Radioimmunotherapy of refractory non-Hodgkin's lymphoma with 131I-labeled chimeric 81C6 anti-tenascin monoclonal antibody:: Dosimetry study.

被引：0

作者：

Akabani, G ^{[1
]}

Rizzieri, D ^{[1
]}

Coleman, RE ^{[1
]}

Metzler, SD ^{[1
]}

Zalutsky, MR ^{[1
]}

Bigner, DD ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Durham, NC 27706 USA

来源：

JOURNAL OF NUCLEAR MEDICINE | 2002年 / 43卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

1259

引用

页码：313P / 313P

页数：1

共 50 条

[21] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
Wagner, HN
Wiseman, GA
Marcus, CS
Nabi, HA
Nagle, CE
Fink-Bennett, DM
Lamonica, DM
Conti, PS
JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (02) : 267 - 272
[22] Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin’s lymphoma
Peter L. Roberson
Hanan Amro
Scott J. Wilderman
Anca M. Avram
Mark S. Kaminski
Matthew J. Schipper
Yuni K. Dewaraja
European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 874 - 883
[23] Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma
Roberson, Peter L.
Amro, Hanan
Wilderman, Scott J.
Avram, Anca M.
Kaminski, Mark S.
Schipper, Matthew J.
Dewaraja, Yuni K.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (05) : 874 - 883
[24] Radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in refractory Hodgkin's lymphoma: preliminary results
Aloj, L.
D'Ambrosio, L.
Aurilio, M.
Morisco, A.
Giovannoni, L.
Mennsen, H. D.
Neri, D.
Caraco, C.
Di Gennaro, F.
Arcamone, M.
Frigeri, F.
Lastoria, S.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S138 - S139
[25] Radioimmunotherapy with 131I anti-CD20 chimeric monoclonal antibody (rituximab) for relapsed or refractory non-Hodgkins lymphoma.
Turner, JH
Martindale, A
Claringbold, PG
Boucek, J
Leahy, MF
JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 115P - 116P
[26] Phase I/II radioimmunotherapy trial with 90Y-labeled epratuzumab (LymphoCide™ anti-CD22 monoclonal antibody) in relapsed/refractory non-Hodgkin's lymphoma (NHL).
Hajjar, G
Burton, JD
Sharkey, RM
Schuster, SL
Czuczman, M
Lamonica, D
Chatal, JF
Alavi, A
Stadtmauer, E
Leonard, JP
Coleman, M
Goldenberg, DM
JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 156P - 156P
[27] Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Advani, Ranjana
Forero-Torres, Andres
Furman, Richard R.
Rosenblatt, Joseph D.
Younes, Anas
Ren, Hong
Harrop, Kate
Whiting, Nancy
Drachman, Jonathan G.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4371 - 4377
[28] Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
Reardon, DA
Akabani, G
Coleman, RE
Friedman, AH
Friedman, HS
Herndon, JE
Cokgor, I
McLendon, RE
Pegram, CN
Provenzale, JM
Quinn, JA
Rich, JN
Regalado, LV
Sampson, JH
Shafman, TD
Wikstrand, CJ
Wong, TZ
Zhao, XG
Zalutsky, MR
Bigner, DD
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1389 - 1397
[29] Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.
Badruddoja, MA
Reardon, DA
Akabani, G
Friedman, AH
Friedman, HS
Rich, JN
Quinn, JA
Penne, K
Vredenburgh, JJ
Bigner, DD
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 124S - 124S
[30] Radioimmunotherapy with I-131-anti-B1 (anti CD20) antibody decreases spleen size in patients with non-Hodgkin's lymphoma
Zasadny, KR
Gates, VL
Kaminski, MS
Wahl, RL
RADIOLOGY, 1998, 209P : 367 - 368

← 1 2 3 4 5 →